Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 661 people with rheumatoid arthritis across four groups. In the first phase (weeks 1 to 12), participants received either a placebo (dummy treatment), upadacitinib 15 mg, or upadacitinib 30 mg daily. The trial was measuring things like joint tenderness and swelling, overall disease activity scores, physical disability, and quality of life — all assessed at the 12-week mark. After week 12, participants continued into a longer follow-up phase lasting up to around five years, with some switching doses along the way. The reported data shows that for the main measures at week 12, 35.7% of people in the placebo group met a standard threshold for meaningful improvement in joint counts and other symptoms (known as ACR20), compared with 63.8% in the 15 mg group and 66.2% in the 30 mg group. For a separate main measure — reaching a "low disease activity" score on a 0–10 scale — 17.2% of the placebo group met that target, compared with 48.4% and 47.9% in the 15 mg and 30 mg groups respectively. The reported data also shows that disease activity scores fell by an average of about 1.0 points in the placebo group, versus around 2.2 and 2.3 points in the two upadacitinib groups. For the physical disability questionnaire (scored 0–3, where lower is better), average scores dropped by 0.25 in the placebo group and by about 0.54–0.59 in the upadacitinib groups. A quality-of-life physical score (where higher is better) rose by an average of 3.03 points with placebo and around 7.6–8.0 points with upadacitinib. Finally, 10% of the placebo group reached the "remission" threshold on the disease activity scale, compared with roughly 28–31% in the upadacitinib groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 40875187) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Rheumatoid Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are a man or woman aged 18 or older.
- You have been diagnosed with rheumatoid arthritis (RA) for at least 3 months.
- You have been taking a standard RA medication (such as methotrexate, sulfasalazine, hydroxychloroquine, chloroquine, or leflunomide) for at least 3 months, and your dose has stayed the same for at least 4 weeks before starting the trial.
- At your screening and baseline appointments, you have at least 6 swollen joints and at least 6 tender joints, meaning your RA is still significantly active.
- You may be eligible if you have previously tried one (and only one) biological RA medication, but only if you had trouble tolerating it or took it for less than 3 months, and you have waited the required amount of time since stopping it (confirm with trial site).
Who may not be able to join:
- You have previously taken a type of medication called a JAK inhibitor, such as tofacitinib, baricitinib, or filgotinib.
- You have a history of another inflammatory joint condition besides rheumatoid arthritis (having secondary Sjögren's Syndrome alongside RA is acceptable).
- Your doctor determines that a biological RA medication you previously tried did not work well enough for you.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: AbbVie Inc., AbbVie
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12; Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.